Meniscal Repair Augmented With Leukocyte-Poor Platelet-Rich Plasma: a Prospective Comparative Clinical Study

This prospective, randomized, comparative, longitudinal clinical study will include 62adult participants aged 18 to 40 years undergoing primary meniscal repair. Participantswill be assigned to two parallel groups: an intervention group receiving leukocyte‐poorplatelet‐rich plasma (LP‐PRP) as biological augmentation during meniscal repair and acontrol group undergoing conventional meniscal repair without biological augmentation.Participants assigned to the intervention group will have approximately 60 mL ofautologous venous blood collected before surgery for preparation of LP‐PRP using astandardized manual double‐centrifugation technique. The LP‐PRP will be activated with10% calcium chloride and applied intraoperatively directly into the meniscal lesionbetween the recently sutured edges. Participants in the control group will undergoconventional meniscal repair without PRP or other biological adjuvants. Surgicaltechniques and postoperative care will otherwise be comparable between groups.Participants will be followed for 6 months. Clinical assessments will be performedpreoperatively and at 2 weeks, 1 month, 3 months, and 6 months after surgery. Painintensity will be evaluated using the Visual Analog Scale (VAS) at all assessment points.Knee function will be evaluated using the International Knee Documentation Committee(IKDC) questionnaire preoperatively and at 3 and 6 months. Return to usual activities andthe occurrence of adverse events or complications will be documented during postoperativefollow‐up.Clinical evaluators, outcome assessors, and data analysts will remain blinded totreatment allocation to minimize measurement and interpretation bias.